About Aavis Pharmaceuticals
Aavis Pharmaceuticals operates as a USFDA-approved contract development and manufacturing organisation (CDMO) focused on generic pharmaceuticals, serving partners who require both development expertise and manufacturing scale under a single roof. Headquartered in the Atlanta region, USA, the company is a privately owned subsidiary of Senores Pharmaceuticals Ltd., operating under the legal entity Havix Group Inc.
The company's core capability centres on the development and manufacture of immediate-release and controlled-release oral solid dosage forms, with a deliberate emphasis on complex formulations that present competitive barriers to entry. This specialisation in technically demanding molecules positions Aavis as a partner for products that require meaningful research input rather than straightforward replication.
Alongside its manufacturing offer, Aavis provides contract research services aimed at developing new formulations for existing drug molecules, with the stated goal of enhancing therapeutic efficiency and improving patient compliance. The organisation describes a management team structured to ensure timely project execution, from early research through to commercial-scale manufacture.
As a USFDA-approved facility, the organisation operates within the regulatory framework required for supply into the US market. Its positioning as one of the faster-growing specialist CDMOs in the generic pharmaceuticals segment reflects the breadth of its integrated research-to-manufacture model.
Further information is available at aavispharmaceuticals.com.
